Picture1.jpg
Sapu BioScience and Cromos Pharma initiating P201 – A Registrational trial for OT-101 in Pancreatic Cancer
August 23, 2023 07:10 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today its joint venture partner, GMP...
Picture1.jpg
High Intra-Tumor TGF-β2 Predicts Poor Survival in Pediatric Cancer of the Brainstem
March 13, 2023 08:00 ET | Oncotelic Therapeutics, Inc.
-The TGFβ1 and TGFβ3 isoforms are predictive --Validation of TGFβ2 as therapeutic target AGOURA HILLS, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC)...
Picture1.jpg
ONCOTELIC REPORTS Q2 2022 COMPARED TO Q2 2021 FINANCIAL RESULTS
August 22, 2022 09:00 ET | Oncotelic Therapeutics, Inc.
Net profit of approximately $17.0 million, upon recording fair value of investment in JV of approximately $22.6 millionReduction in expenses in Q2 2022 versus Q2 2021 by over $3.5M, AGOURA HILLS,...
Picture1.jpg
Oncotelic Appoints Seymour Fein M.D. as Chief Regulatory Officer
May 04, 2022 07:00 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), today announced the appointment of Dr. Seymour Fein as its Chief...
Picture1.jpg
Oncotelic Appoints Fatih Uckun, M.D., Ph.D., as Chief Medical Officer
May 03, 2022 07:00 ET | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company” or “We”) (OTCQB:OTLC), today announced the appointment of Dr. Fatih Uckun as its...
Logo.jpg
Celsion Corporation Announces Closing of Public Offering of Common Stock
June 24, 2020 16:15 ET | Celsion CORP
Lawrenceville, NJ, June 24, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the closing of its previously announced public offering...
Logo.jpg
Celsion Receives $2.5 Million in Non-Dilutive Funding from the Sale of its New Jersey State Net Operating Losses and Grant Funding Under the Paycheck Protection Program
April 23, 2020 08:30 ET | Celsion CORP
Added Capital Strengthens Balance Sheet, Assures Cash Through Major Phase III OPTIMA Study Data Readout Events Sale of an Additional $2.0 Million of NOL’s Expected in the 4th Quarter of 2020 ...
Logo.jpg
Celsion’s GEN-1 Immunotherapy Receives Orphan Drug Designation from the European Medicines Agency
March 23, 2020 08:00 ET | Celsion CORP
Approval Adds 10 Years of Market Exclusivity Following Marketing Authorization in Europe LAWRENCEVILLE, N.J., March 23, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a leading...
Logo.jpg
Celsion CEO Issues Letter to Stockholders
March 03, 2020 08:30 ET | Celsion CORP
LAWRENCEVILLE, N.J., March 03, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announces that Michael H. Tardugno, the company’s chairman,...